Adamas Pharma (ADMS): Strong Balance Sheet & Cost Containment in 3Q:16 - Mizuho

November 7, 2016 7:14 AM EST
Get Alerts ADMS Hot Sheet
Price: $15.66 -1.57%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade ADMS Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on shares of Adamas Pharmaceuticals (NASDAQ: ADMS) after announcing a bottom line "beat" driven by reduced spending.

The company also disclosed a $200M shelf filing, and a potential $22.3M secondary offering at $13.91, which should bolster its balance sheet in the unlikely scenario the company decided to go it alone rather than be acquired. The analyst still views ADMS as a likely takeout target in 2017 and reiterated her $26 PT.

For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.

Shares of Adamas Pharmaceuticals closed at $13.93 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Earnings

Related Entities

Irina Koffler

Add Your Comment